Cargando…

Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies

Aims: The aim of the study was to investigate the efficacy and safety of as-needed use of nalmefene 18 mg versus placebo in reducing alcohol consumption in patients who did not reduce their alcohol consumption after an initial assessment, i.e. the pooled subgroup of patients with at least a high dri...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Brink, Wim, Aubin, Henri-Jean, Bladström, Anna, Torup, Lars, Gual, Antoni, Mann, Karl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746807/ https://www.ncbi.nlm.nih.gov/pubmed/23873853 http://dx.doi.org/10.1093/alcalc/agt061

Ejemplares similares

Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene
por: Luquiens, Amandine, et al.
Publicado: (2014)

Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene
por: Foo, Jerome Clifford, et al.
Publicado: (2019)

The More You Take It, the Better It Works: Six-Month Results of a Nalmefene Phase-IV Trial
por: Barrio, Pablo, et al.
Publicado: (2019)

The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
por: François, Clément, et al.
Publicado: (2015)

Nalmefene in alcohol‐dependent patients with a high drinking risk: Randomized controlled trial
por: Miyata, Hisatsugu, et al.
Publicado: (2019)

Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response
por: Witkiewitz, Katie, et al.
Publicado: (2019)

Automatic Avoidance Tendencies for Alcohol Cues Predict Drinking After Detoxification Treatment in Alcohol Dependence
por: Field, Matt, et al.
Publicado: (2016)

Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels
por: Witkiewitz, Katie, et al.
Publicado: (2016)

Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder
por: Karl, Damian, et al.
Publicado: (2021)

Response to ‘Nalmefene in alcohol‐dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption’
por: Higuchi, Susumu, et al.
Publicado: (2020)

Nalmefene: a new approach to the treatment of alcohol dependence
por: Paille, François, et al.
Publicado: (2014)

Emotion differentiation in early recovery from alcohol use disorder: Associations with in‐the‐moment affect and 3‐month drinking outcomes
por: Emery, Noah N., et al.
Publicado: (2022)

Development of a Psychologically Enhanced Interactive Online Intervention for Hazardous Drinking
por: Linke, Stuart, et al.
Publicado: (2008)

The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study
por: Grundinger, Nadja, et al.
Publicado: (2022)

Nalmefene: a new approach to the treatment of alcohol dependence [Corrigendum]
Publicado: (2015)

Evaluation in alcohol use disorders – insights from the nalmefene experience
por: Naudet, Florian, et al.
Publicado: (2016)

Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial
por: Witkiewitz, Katie, et al.
Publicado: (2019)

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
por: Toussirot, Éric, et al.
Publicado: (2016)

The Alcohol Improvement Programme: Evaluation of an Initiative to Address Alcohol-Related Health Harm in England
por: Thom, Betsy, et al.
Publicado: (2013)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
por: Rossignol, Patrick, et al.
Publicado: (2020)

Long‐term safety and efficacy of nalmefene in Japanese patients with alcohol dependence
por: Higuchi, Susumu, et al.
Publicado: (2020)

Does state repeal of alcohol exclusion laws increase problem drinking?
por: Azagba, Sunday, et al.
Publicado: (2022)

The Impact of Brief Alcohol Interventions in Primary Healthcare: A Systematic Review of Reviews
por: O'Donnell, Amy, et al.
Publicado: (2014)

Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?
por: Braillon, Alain, et al.
Publicado: (2015)

Clinical relevance of nalmefene versus placebo in alcohol treatment: Reduction in mortality risk
por: Roerecke, Michael, et al.
Publicado: (2015)

Navigating the Alcohol Treatment Pathway: A Qualitative Study from the Service Users' Perspective
por: Gilburt, Helen, et al.
Publicado: (2015)

“Doctor, Can I Drink an Alcohol-Free Beer?” Low-Alcohol and Alcohol-Free Drinks in People with Heavy Drinking or Alcohol Use Disorders: Systematic Review of the Literature
por: Caballeria, Elsa, et al.
Publicado: (2022)

Twelve-Month Follow-up Results from a Randomized Controlled Trial of a Brief Personalized Feedback Intervention for Problem Drinkers
por: Cunningham, John A., et al.
Publicado: (2010)

Awareness and Treatment of Alcohol Dependence in Japan: Results from Internet-Based Surveys in Persons, Family, Physicians and Society
por: Taguchi, Yurie, et al.
Publicado: (2014)

Intervention against Excessive Alcohol Consumption in Primary Health Care: A Survey of GPs' Attitudes and Practices in England 10 Years On
por: Wilson, Graeme B., et al.
Publicado: (2011)

Early Treatment for Women with Alcohol Addiction (EWA) Reduces Mortality: A Randomized Controlled Trial with Long-Term Register Follow-up
por: Gjestad, Rolf, et al.
Publicado: (2011)

Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis
por: Aubin, Henri-Jean, et al.
Publicado: (2021)

Anxiety, Anxiety Sensitivity, and Perceived Stress as Predictors of Recent Drinking, Alcohol Craving, and Social Stress Response in Heavy Drinkers
por: McCaul, Mary E., et al.
Publicado: (2017)

Biosimilars: what do patients need to consider?
por: Skingle, Diana
Publicado: (2015)

Use of nitrous oxide in children with special health care needs
por: Ritwik, Priyanshi, et al.
Publicado: (2020)

Post-treatment Stage of Change Predicts 12-month Outcome of Treatment for Alcohol Problems
por: Heather, Nick, et al.
Publicado: (2013)

Corrigendum to: Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis
por: Aubin, Henri-Jean, et al.
Publicado: (2021)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Can Alcohol Use Disorder Recovery Include Some Heavy Drinking? A Replication and Extension up to 9 Years Following Treatment
por: Witkiewitz, Katie, et al.
Publicado: (2020)

In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene
por: Xie, Xiangyang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_esfq8g4ta1i0rmhb9tvol0os5f